These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 15245690)

  • 21. Clinical effectiveness and cost-effectiveness of imatinib dose escalation for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours that have progressed on treatment at a dose of 400 mg/day: a systematic review and economic evaluation.
    Hislop J; Quayyum Z; Elders A; Fraser C; Jenkinson D; Mowatt G; Sharma P; Vale L; Petty R
    Health Technol Assess; 2011 Jun; 15(25):1-178. PubMed ID: 21689502
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of nilotinib, dasatinib and imatinib as first-line treatment for chronic myeloid leukemia in Colombia, 2012.
    Romero M; Chávez D; De Los Ríos M; Alvis-Guzmán N
    Biomedica; 2014; 34(1):48-59. PubMed ID: 24968906
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha.
    Kantarjian HM; Cortes JE; O'Brien S; Luthra R; Giles F; Verstovsek S; Faderl S; Thomas D; Garcia-Manero G; Rios MB; Shan J; Jones D; Talpaz M
    Blood; 2004 Oct; 104(7):1979-88. PubMed ID: 15198956
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.
    Druker BJ; Guilhot F; O'Brien SG; Gathmann I; Kantarjian H; Gattermann N; Deininger MW; Silver RT; Goldman JM; Stone RM; Cervantes F; Hochhaus A; Powell BL; Gabrilove JL; Rousselot P; Reiffers J; Cornelissen JJ; Hughes T; Agis H; Fischer T; Verhoef G; Shepherd J; Saglio G; Gratwohl A; Nielsen JL; Radich JP; Simonsson B; Taylor K; Baccarani M; So C; Letvak L; Larson RA;
    N Engl J Med; 2006 Dec; 355(23):2408-17. PubMed ID: 17151364
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation.
    Wilson J; Connock M; Song F; Yao G; Fry-Smith A; Raftery J; Peake D
    Health Technol Assess; 2005 Jul; 9(25):1-142. PubMed ID: 15985189
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
    Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness study comparing imatinib with interferon-alpha for patients with newly diagnosed chronic-phase (CP) chronic myeloid leukemia (CML) from the Chinese public health-care system perspective (CPHSP).
    Chen Z; Wang C; Xu X; Feng W
    Value Health; 2009; 12 Suppl 3():S85-8. PubMed ID: 20586990
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Imatinib mesylate, the first molecularly targeted gene suppressor.
    Pindolia VK; Zarowitz BJ
    Pharmacotherapy; 2002 Oct; 22(10):1249-65. PubMed ID: 12389876
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of interferon-alpha and conventional chemotherapy in chronic myelogenous leukemia.
    Kattan MW; Inoue Y; Giles FJ; Talpaz M; Ozer H; Guilhot F; Zuffa E; Huber SL; Beck JR
    Ann Intern Med; 1996 Oct; 125(7):541-8. PubMed ID: 8815752
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-Effectiveness of First-Line Tyrosine Kinase Inhibitor Therapy Initiation Strategies for Chronic Myeloid Leukemia.
    Nguyen JT; Cole AL; Leech AA; Wood WA; Dusetzina SB
    Value Health; 2020 Oct; 23(10):1292-1299. PubMed ID: 33032772
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reversal of bone marrow angiogenesis in chronic myeloid leukemia following imatinib mesylate (STI571) therapy.
    Kvasnicka HM; Thiele J; Staib P; Schmitt-Graeff A; Griesshammer M; Klose J; Engels K; Kriener S
    Blood; 2004 May; 103(9):3549-51. PubMed ID: 14726401
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
    Paschka P; Müller MC; Merx K; Kreil S; Schoch C; Lahaye T; Weisser A; Petzold A; König H; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2003 Sep; 17(9):1687-94. PubMed ID: 12970765
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States.
    Padula WV; Larson RA; Dusetzina SB; Apperley JF; Hehlmann R; Baccarani M; Eigendorff E; Guilhot J; Guilhot F; Hehlmann R; Mahon FX; Martinelli G; Mayer J; Müller MC; Niederwieser D; Saussele S; Schiffer CA; Silver RT; Simonsson B; Conti RM
    J Natl Cancer Inst; 2016 Jul; 108(7):. PubMed ID: 26944912
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of dasatinib and nilotinib for imatinib-resistant or -intolerant chronic phase chronic myeloid leukemia.
    Hoyle M; Rogers G; Moxham T; Liu Z; Stein K
    Value Health; 2011 Dec; 14(8):1057-67. PubMed ID: 22152175
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nilotinib versus dasatinib as second-line therapy in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase who are resistant or intolerant to imatinib: a cost-effectiveness analysis based on real-world data.
    Li N; Yang X; Fan L; Totev T; Guerin A; Chen L; Bhattacharyya S; Joseph G
    J Med Econ; 2017 Apr; 20(4):328-336. PubMed ID: 27841717
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Five-year follow-up of patients treated with imatinib mesylate for chronic myeloid leukaemia in Trinidad and Tobago.
    Charles KS; Ramon L; Leelah N; Oluwabusi TA; Seemungal T
    West Indian Med J; 2011 Jun; 60(3):298-302. PubMed ID: 22224342
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
    Cortes J; Talpaz M; O'Brien S; Giles F; Beth Rios M; Shan J; Faderl S; Garcia-Manero G; Ferrajoli A; Wierda W; Kantarjian H
    Cancer; 2003 Sep; 98(6):1105-13. PubMed ID: 12973833
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Progression of chronic myeloid leukemia to blast crisis during treatment with imatinib mesylate.
    Xu Y; Wahner AE; Nguyen PL
    Arch Pathol Lab Med; 2004 Sep; 128(9):980-5. PubMed ID: 15338554
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Societal implications of medical insurance coverage for imatinib as first-line treatment of chronic myeloid leukemia in China: a cost-effectiveness analysis.
    Sheng G; Chen S; Dong C; Zhang R; Miao M; Wu D; Tan SC; Liu C; Xiong T
    J Med Econ; 2017 Apr; 20(4):371-381. PubMed ID: 27936995
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-efficacy of imatinib versus allogeneic bone marrow transplantation with a matched unrelated donor in the treatment of chronic myelogenous leukemia: a decision-analytic approach.
    Skrepnek GH; Ballard EE
    Pharmacotherapy; 2005 Mar; 25(3):325-34. PubMed ID: 15843279
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.